These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Development of biologicals for the therapy of lupus erythematosus. Neumann D; Tschernig T; Boraschi D Expert Rev Vaccines; 2007 Dec; 6(6):1001-11. PubMed ID: 18034656 [TBL] [Abstract][Full Text] [Related]
3. Immunopathology and the gene therapy of lupus. Mageed RA; Prud'homme GJ Gene Ther; 2003 May; 10(10):861-74. PubMed ID: 12732872 [TBL] [Abstract][Full Text] [Related]
4. Immune cells and cytokines in systemic lupus erythematosus: an update. Kyttaris VC; Juang YT; Tsokos GC Curr Opin Rheumatol; 2005 Sep; 17(5):518-22. PubMed ID: 16093827 [TBL] [Abstract][Full Text] [Related]
5. Immunopathological roles of cytokines, chemokines, signaling molecules, and pattern-recognition receptors in systemic lupus erythematosus. Yu SL; Kuan WP; Wong CK; Li EK; Tam LS Clin Dev Immunol; 2012; 2012():715190. PubMed ID: 22312407 [TBL] [Abstract][Full Text] [Related]
6. SiLEncing SLE: the power and promise of small noncoding RNAs. Rigby RJ; Vinuesa CG Curr Opin Rheumatol; 2008 Sep; 20(5):526-31. PubMed ID: 18698172 [TBL] [Abstract][Full Text] [Related]
7. The immunological basis of B-cell therapy in systemic lupus erythematosus. Mok MY Int J Rheum Dis; 2010 Feb; 13(1):3-11. PubMed ID: 20374380 [TBL] [Abstract][Full Text] [Related]
13. Attempt to correct abnormal signal transduction in T lymphocytes from systemic lupus erythematosus patients. Fujii Y; Fujii K; Tanaka Y Autoimmun Rev; 2006 Feb; 5(2):143-4. PubMed ID: 16431347 [TBL] [Abstract][Full Text] [Related]
14. [Biological therapies of systemic lupus erythematosus]. Olesińska M; Chwalińska-Sadowska H; Mielnik P; Wiesik-Szewczyk E Pol Merkur Lekarski; 2006 Mar; 20(117):371-3. PubMed ID: 16780279 [TBL] [Abstract][Full Text] [Related]
15. T cells as a therapeutic target in SLE. Comte D; Karampetsou MP; Tsokos GC Lupus; 2015 Apr; 24(4-5):351-63. PubMed ID: 25801878 [TBL] [Abstract][Full Text] [Related]
16. An Insight on the Pathogenesis and Treatment of Systemic Lupus Erythematosus. Ali M; Firoz CK; Jabir NR; Rehan M; Khan MS; Tabrez S Endocr Metab Immune Disord Drug Targets; 2018 Feb; 18(2):110-123. PubMed ID: 29219063 [TBL] [Abstract][Full Text] [Related]
17. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus. Mihaylova N; Bradyanova S; Chipinski P; Herbáth M; Chausheva S; Kyurkchiev D; Prechl J; Tchorbanov AI Autoimmunity; 2017 Jun; 50(4):257-268. PubMed ID: 28300427 [TBL] [Abstract][Full Text] [Related]
18. T lymphocytes in systemic lupus erythematosus: an update. Kyttaris VC; Tsokos GC Curr Opin Rheumatol; 2004 Sep; 16(5):548-52. PubMed ID: 15314492 [TBL] [Abstract][Full Text] [Related]
19. Pathways leading to an immunological disease: systemic lupus erythematosus. Zharkova O; Celhar T; Cravens PD; Satterthwaite AB; Fairhurst AM; Davis LS Rheumatology (Oxford); 2017 Apr; 56(suppl_1):i55-i66. PubMed ID: 28375453 [TBL] [Abstract][Full Text] [Related]
20. Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies. Lee HJ; Sinha AA Autoimmunity; 2006 Sep; 39(6):433-44. PubMed ID: 17060022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]